Phanginin A 

Phanginin A is a potent and orally active SIK1 (salt-induced kinase 1) activator. Phanginin A inhibited gluconeogenesis. Phanginin A increases the expression of p-SIK1 and decreases the expression of p-CREB. Phanginin A reduces blood glucose levels and improves glucose tolerance and dyslipidemia. Phanginin A has the potential for the research of type 2 diabetes^[1].

Phanginin A (2.5, 5, 10 µM) suppresses gluconeogenesis in primary mouse hepatocytes in a dose-dependent manner^[1].
Phanginin A (5, 10 µM) reduces the mRNA expression of G6P and PEPCK, and decreases the intracellular cAMP accumulation^[1].
Phanginin A (5, 10 µM; 0-120 min) inhibits the expression of CREB phosphorylation in a time and dose-dependent manner in primary mouse hepatocytes^[1].
Phanginin A (2.5, 5, 10 µM; 0-120 min) increases the expression of p-SIK1 in a time and dose-dependent manner in primary mouse hepatocytes^[1].
Phanginin A (5, 10 µM) increases PDE4 activity^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Phanginin A (100 mg/kg; p.o.; once) shows anti-gluconeogenesis activity in type 2 diabetic ob/ob mice^[1].
Phanginin A (100 mg/kg; p.o.; once daily for 26 days) improves metabolic disorders in ob/ob mice^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

360.44

C₂₁H₂₈O₅

1011528-58-7

O[[email protected]]1[[email protected]@]23[[email protected]](CC[[email protected]]4([H])[[email protected]]3([H])CC5=C(C=CO5)[[email protected]@H]4C)([H])[[email protected]@](CO1)(CCC2)C(OC)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liu S, et al. Activation of SIK1 by phanginin A inhibits hepatic gluconeogenesis by increasing PDE4 activity and suppressing the cAMP signaling pathway. Mol Metab. 2020 Nov;41:101045.  [Content Brief]